Yujue Wang

Yujue Wang

Auto-generated profile, based on publicly available information

Yujue Wang

Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Cancer Cell
Verified
Journal Article
Open access
YWYujue Wang
Yujue Wang
SLSixue Liu
Sixue Liu
ZYZhentao Yang
Zhentao Yang
AAAlain P. Algazi
Alain P. Algazi
SLShirley H. Lomeli
Shirley H. Lomeli
RLRoger S. Lo
Roger S. Lo
Rationally sequencing and combining PD-1/L1-and MAPK-targeted therapies may overcome innate and acquired resistance. Since increased clinical benefit of MAPK inhibitors (MAPKi) is associated with previous immune checkpoint therapy, we compare the efficacies of sequential and/or combinatorial regimens in subcutaneous murine models of melanoma driven by BrafV600, Nras, or Nf1 mutations as well as colorectal and pancreatic carcinoma driven by KrasG12C. Anti-PD-1/L1 lead-in preceding MAPKi combination optimizes response durability by promoting pro-inflammatory polarization of macrophages and clonal expansion of interferon-γhi, and CD8+ cytotoxic and proliferative (versus CD4+ regulatory) T cells that highly express activation genes. Since therapeutic resistance of melanoma brain metastasis (MBM) limits patient survival, we demonstrate that sequencing anti-PD-1/L1 therapy before MAPKi combination suppresses MBM and improves mouse survival with robust T cell clonal expansion in both intracranial and extracranial metastatic sites. We propose clinically testing brief anti-PD-1/L1 (± anti-CTLA-4) dosing before MAPKi co-treatment to suppress therapeutic resistance.

24 August 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
DLDaijin Li
Daijin Li
JXJing Xu
Jing Xu
JCJie Chang
Jie Chang
YWYujue Wang
Yujue Wang
XDXiaoye Du
Xiaoye Du
YCYu Chen
Yu Chen
Background: Photoreceptor degeneration underpinned by oxidative stress-mediated mitochondrial dysfunction and cell death leads to progressive and irreversible vision impairment. Drug treatments that protect against photoreceptor degeneration are currently available in the clinical settings. It has been shown that hyperoside, a flavonol glycoside, protects against neuronal loss in part by suppressing oxidative stress and maintaining the functional integrity of mitochondria. However, whether hyperoside protects against photoreceptor degeneration remains unknown. Methods: To address the pharmacological potentials of hyperoside against oxidative stress-mediated photoreceptor degeneration on molecular, cellular, structural and functional levels, multiple in vitro and in vivo methodologies were employed in the current study, including live-cell imaging, optical coherence tomography, electroretinography, histological/immunohistochemical examinations, transmission electron microscopy, RNA-sequencing and real-time qPCR. Results: The in vitro results demonstrate that hyperoside suppresses oxidative stress-mediated photoreceptor cell death in part by mitigating mitochondrial dysfunction. The in vivo results reveal that hyperoside protects against photooxidative stress-induced photoreceptor morphological, functional and ultrastructural degeneration. Meanwhile, hyperoside treatment offsets the deleterious impact of photooxidative stress on multiple molecular pathways implicated in the pathogenesis of photoreceptor degeneration. Lastly, hyperoside attenuates photoreceptor degeneration-associated microglial inflammatory activation and reactive Müller cell gliosis. Conclusions: All things considered, the present study demonstrates for the first time that hyperoside attenuates oxidative stress-induced photoreceptor mitochondrial dysfunction and cell death. The photoreceptor-intrinsic protective effects of hyperoside are corroborated by hyperoside-conferred protection against photooxidative stress-mediated photoreceptor degeneration and perturbation in retinal homeostasis, warranting further evaluation of hyperoside as a photoreceptor protective agent for the treatment of related photoreceptor degenerative diseases.

10 April 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
LDLiyun Dong
Liyun Dong
NWNaming Wu
Naming Wu
ZCZhen Cai
Zhen Cai
SYShiyi Yan
Shiyi Yan
JPJuan Pan
Juan Pan
JTJuan Tao
Juan Tao
Langerhans cells (LCs), as epidermal-resident antigen-presenting cells, are among the first to encounter early carcinogenic changes in the skin, such as those seen in melanoma. During inflammation or cancer, circulating monocytes are recruited into the epidermis, replacing resident LCs (rLCs) that have migrated to draining lymph nodes. However, the specific roles of LC subsets in the progression of melanoma remain unclear. Here, we observed a decrease in rLCs and an increase in monocyte-derived LCs (moLCs) within melanoma tumor tissues as the disease progressed. Notably, the frequency of moLCs was higher in patients with anti-PD-1 therapy-resistant melanoma than in those responsive to the therapy. Using muLangerin-DTR transgenic and moLC-specific knockout mouse models, we demonstrated that the depletion of rLCs accelerated melanoma growth, whereas the depletion of moLCs suppressed tumor progression. Mechanistically, moLCs exhibited elevated expression of COX2-related genes compared to rLCs. TGF-β was found to activate aryl hydrocarbon receptor (AhR)-COX2 signaling in moLCs, leading to increased production of PGE2 and expression of PD-L1, which collectively contributed to the immunosuppressive effects of moLCs on CD8+CTLs. In summary, our findings highlight the functional heterogeneity of LC subsets in melanoma progression, offering deeper insights into LC biology and potential therapeutic strategies.

1 December 2020 in European Journal Of Dermatology
Verified
Journal Article
Open access
LZLiang Zhao
Liang Zhao
HDHongyao Du
Hongyao Du
MAMahin Alamgir
Mahin Alamgir
JYJing Yang
Jing Yang
XMXiaoping Miao
Xiaoping Miao
JTJuan Tao
Juan Tao

29 July 2025 in Biomaterials
Verified
Journal Article
Closed access
TMTianyue Ma
Tianyue Ma
FZFei Zhang
Fei Zhang
YPYumeng Pan
Yumeng Pan
ZLZiyi Li
Ziyi Li
YWYujue Wang
Yujue Wang
ZWZejun Wang
Zejun Wang

13 April 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
Xiaoyang SuXiaoyang Su
Xiaoyang Su
YWYujue Wang
Yujue Wang
CCCecilia Colson
Cecilia Colson